These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 29417883)
1. Patent highlights October-November 2017. Mucke HA Pharm Pat Anal; 2018 Mar; 7(2):73-81. PubMed ID: 29417883 [TBL] [Abstract][Full Text] [Related]
2. Patent highlights April-May 2020. Mucke HA Pharm Pat Anal; 2020 Sep; 9(5):139-146. PubMed ID: 32959701 [TBL] [Abstract][Full Text] [Related]
3. Patent Highlights August-September 2018. Mucke HA Pharm Pat Anal; 2019 Jan; 8(1):7-14. PubMed ID: 30869551 [TBL] [Abstract][Full Text] [Related]
4. Patent highlights December 2019-January 2020. Mucke HA Pharm Pat Anal; 2020 May; 9(3):67-74. PubMed ID: 32539539 [TBL] [Abstract][Full Text] [Related]
5. Should the patent system for new medicines be abolished? DiMasi JA; Grabowski HG Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100 [No Abstract] [Full Text] [Related]
6. Evaluation of similar biotherapeutic products: scientific and regulatory challenges. Griffiths E; Thorpe R; Wadhwa M; Sohn Y Biologicals; 2011 Sep; 39(5):249. PubMed ID: 21925898 [No Abstract] [Full Text] [Related]
7. Patent highlights October-November 2019. Mucke HA Pharm Pat Anal; 2020 May; 9(2):33-40. PubMed ID: 32301373 [TBL] [Abstract][Full Text] [Related]
8. Herbal drug patenting in India: IP potential. Sahoo N; Manchikanti P; Dey SH J Ethnopharmacol; 2011 Sep; 137(1):289-97. PubMed ID: 21640810 [TBL] [Abstract][Full Text] [Related]
9. The right to a trial: Should dying patients have access to experimental drugs? Groopman J New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539 [No Abstract] [Full Text] [Related]
10. Sources of innovation: an assessment of intellectual property. Kinch MS; Raffo J Drug Discov Today; 2015 May; 20(5):500-4. PubMed ID: 25499663 [TBL] [Abstract][Full Text] [Related]
11. Patent protection in Europe of pharmaceuticals found to have a further medical indication. Cockbain J Pharm Pat Anal; 2012 Mar; 1(1):17-8. PubMed ID: 24236708 [No Abstract] [Full Text] [Related]
12. The interaction between intellectual property and drug regulatory systems: global perspectives. Madden EA IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464 [TBL] [Abstract][Full Text] [Related]
13. Enforcing pharmaceutical and biotech patent rights in China. Zhang YP; Deng MM Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760 [No Abstract] [Full Text] [Related]
16. Patent term extension: an overreaching solution to a nonexistent problem. Engelberg AB Health Aff (Millwood); 1982; 1(2):34-45. PubMed ID: 10621693 [No Abstract] [Full Text] [Related]
17. IP litigation in China could drive innovation. Jia H Nat Biotechnol; 2004 Apr; 22(4):368. PubMed ID: 15060539 [No Abstract] [Full Text] [Related]
18. Misleading data in pharmaceutical and biological patent specifications: best mode after the America Invents Act. Laporte C; Deneke CC; Banks D Pharm Pat Anal; 2015; 4(4):247-51. PubMed ID: 26174564 [No Abstract] [Full Text] [Related]